In a clinical trial investigating the efficacy and safety of CD19 CAR T-cell therapy, 22 patients with B-cell lymphoma were enrolled, including 12 patients with R/R B-cell lymphoma and 10 patients who were minimal residual disease (MRD) positive. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.